Literature DB >> 1575003

Suppression of active but not passive autoimmune encephalomyelitis by dual cyclo-oxygenase and 5-lipoxygenase inhibition.

R D Simmons1, A R Hugh, D O Willenborg, W B Cowden.   

Abstract

Previous research has shown that the dual cyclo-oxygenase and 5-lipoxygenase inhibitor, BW755c suppresses experimental autoimmune encephalomyelitis (EAE). In the present study, the effects of BW755c on both actively and passively induced EAE in the Lewis rat were examined, and also its effect on the accumulation of radiolabeled spleen cells in response to direct injection of tumor necrosis factor into the spinal cord. It was found that BW755c suppressed actively induced EAE but not passively induced EAE nor cytokine-induced cell accumulation in the central nervous system. It is concluded that arachidonic acid metabolites may be important in the induction phase of EAE, but do not appear to be crucial to the effector phase of EAE.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1575003     DOI: 10.1111/j.1600-0404.1992.tb04027.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

1.  Cyclooxygenase-1 and -2 in brains of patients who died with sporadic Creutzfeldt-Jakob disease.

Authors:  Martin H Deininger; Kubrom Bekure-Nemariam; Katrin Trautmann; Matthias Morgalla; Richard Meyermann; Hermann J Schluesener
Journal:  J Mol Neurosci       Date:  2003-02       Impact factor: 3.444

2.  Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis.

Authors:  Athena Kalyvas; Constantinos Baskakis; Victoria Magrioti; Violetta Constantinou-Kokotou; Daren Stephens; Rubèn López-Vales; Jian-Qiang Lu; V Wee Yong; Edward A Dennis; George Kokotos; Samuel David
Journal:  Brain       Date:  2009-02-13       Impact factor: 13.501

Review 3.  Developing therapeutics for the treatment of multiple sclerosis.

Authors:  David J Virley
Journal:  NeuroRx       Date:  2005-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.